Search

Welcome to the EHA2025 Sponsor Program

On this page, you can browse and/or download the interactive EHA2025 Sponsor Program. If the EHA2025 Sponsor Program does not display correctly, please click here or download the file.

Publications

Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review
Neuendorff NR, Khan A, Ullrich F, Yates S, Devarakonda S, Lin RJ, von Tresckow B, Cordoba R, Artz A, Rosko AE. J Geriatr Oncol. 2024 Feb 29;15(3):101734.

Highlights from the SWG

EventsParticipation in the 19th European LeukemiaNet (ELN) SymposiumLocation and dateThis event was held in Mannheim, Germany, on April 18, 2023. Chairs
D. Hoelzer
S. Chiaretti
Topics
Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands). Inotuzumab ozogamicin in MRD+ ALL (G.

SWG Educational Activities

MeetingsEHA SWG EWALL SymposiumLocation and dateThis meeting was held in Frankfurt in June 2023 as part of EHA2023. TopicPersonalized ALL therapy. ChairNicola Gokbuget

Sessions and speakers
B-cell precursor ALL, the Finnish experience (Kimmo Porkka).

Publications

The EBMT/EHA CAR-T Cell Handbook
Editors: Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele. 2022, ISBN 978-3-030-94352-3 ISBN 978-3-030-94353-0 (eBook).

Chairs and Members

Chair (until 2026)Hermann Einsele, Professor of Hematology and Oncology, University Hospital Würzburg (Germany)

Co-chair (until 2026)Arjan van de Loosdrecht, Professor of Hematology and Immunhematology, Amsterdam UMC (The Netherlands)

SWG Steering Committee members
Jorge Sierra, Professor of Hematology, Hospital Santa Creu I Sant Pau…

Chairs and Members

Chairs
Chair ESLHO: Prof Dr J. J. M. van Dongen, USAL, Salamanca, Spain
Chair EuroFlow: Prof Dr J. J. M van Dongen, USAL, Salamanca, Spain
Chair EuroMRD: Prof Dr M.

Highlights from the SWG

The European Scientific foundation for Laboratory Hemato Oncology (ESLHO), together with the three scientific consortia of EuroClonality, EuroMRD, and EuroFlow, share the same four goals:

Research and innovation of diagnostic patient care
Standardization of laboratory diagnostics
Quality assessment
Education
ESLHO supports the three consortia in…

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

European Scientific foundation for Laboratory Hemato Oncology (ESLHO)

The objectives of ESLHO are to promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies, as well as to facilitate quality control and education in this field.